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Pulmonary Vein Electrical Isolation for the Cure of Paroxysmal
Atrial Fibrillation Guided by a Novel Geometry Mapping System
CAIYI LU, SHIWEN WANG, XINPING DU, YINGLONG HOU, QIAO XUE, XINLI WU, RUI CHEN,
PENG LIU
From The Institute of Geriatric Cardiology, 301 Hospital, Beijing, China
LU ET AL.: Pulmonary Vein Electrical Isolation for the Cure of Paroxysmal Atrial Fibrillation Guided by a
Novel Geometry Mapping System. Objectives: The purpose of the study is to evaluate the feasibility and effect
of left wall (LA) ablation guided by a novel geometry mapping system in the treatment of older patients with
paroxysmal atrial fibrillation (PAF). Methods: Regular electrophysiological study was conducted to exclude
atrioventricular reentrant tachycardia (AVRT) with accessory pathways, atrioventricular nodal reentrant
tachycardia (AVNRT) and other inducible tachyarrhythmias. Twice transseptal puncture was achieved with L1
and R1 Swartz sheaths. Pulmonary vein (PV) angiographies were conducted to evaluate their orifices and
branches. LA geometry was constructed under either sinus rhythm or PAF using Ensite3000 Navx system. Two
lesion loops and three lines (see details in the text) for electrical isolation were outlined and created by
radiofrequency catheter ablation on the three-dimension geometry of LA. Each lesion point was ablated in 30
seconds with preset temperature 50°C and energy 30W. The disappearance or 80% decrease of the amplitude
of LA target potential and 10 to 20 Ω decrease of ablation impedance were used as effective index. Results:
Three patients included two males and one female of age 67.3±3.6. PAF history was 7.4±5.1 years. Mean 3.5±
1.2 antiarrhythmic agents were used in 5.7±2.3 years without PAF effectively prevention. No organic heart
diseases and stroke complications were founded. Left atrium was 38.7±3.2 mm and LVEF was 58.6±4.3 on
echocardiography. Altogether 59-126 (63.7±11.2) lesion points were created to complete two loops and
three lines. Rapid burst pacing up to 600 beats per minute was delivered from the distal coronary sinus
electrode pair without PAF provoked. The procedure time was 2.8±0.7 hours and fluoroscopy time was 19.6±
8.3 minutes. Patients were discharged with long-term oral warfarin and without any antiarrhythmic agent.
During the follow up of 5.6±2.3 months, one patient was free of symptom and PAF attacks were decreased more
than 80% in the other two patients by evaluation of Holter monitoring. Conclusions: Ensite3000 Navx guided
LA wall ablation near PV orifice to cure PAF in the elderly is safe and feasible and has the advantages of clear
procedure endpoint, shorter X-ray exposure, less complication and satisfied long-term effect. Large number of
cases and long-term follow up data are needed to validate these primary results. (J HK Coll Cardiol 2004;12:
58-63)
Electrophysiology, paroxysmal atrial fibrillation, radiofrequency ablation
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Paroxysmal atrial fibrillation (PAF) in elderly
is usually triggered or driven by electrical foci
originated from atrial muscle sleeves (AMS) mostly
from pulmonary veins. 1 PAF could be cured either
by ablating AMS focus or isolating target AMS
electrically.2,3 Due to the high recurrence rate of the
former technique, later therapies are more frequently
used in clinical interventive electrophysiology. 4
Radiofrequency (RF) catheter ablation at the orifice
of target pulmonary vein (TPV) was used at first in
the cure of PAF, but early and long-term stenosis of
TPV limited the usage of the method. 3-5 Therefore,
novel non-contact geometry mapping systems are
used to guide the isolation of AMS in the left atrial
wall just near their orifice.6 Ensite3000 Navx is one
of these new systems. The main difference between
Ensite3000 Navx and Carto quick map is the former
adapts a regular RF large tip catheter to construct
left atrial and AMS geometry and creates the RF
lesion circles or lines at either sinus rhythm or PAF
rhythm. Three older PAF patients were treated with
Ensite3000 Navx and clinical effect and experience
were reported.

Clinical Data
Three patients included two males and one
female of age 67.3±3.6. PAF history was 7.4±5.1
years. Mean 3.5±1.2 antiarrhythmic agents
(including amiodarone, propafenone, propranolol,
sotalol, quinidine, etc.) were used in 5.7±2.3 yeas
without PAF effectively prevention. One male

59

10~20Ω
3.5 1.2
59-126 (63.7 11.2)
19.6 8.3
5.6

2.3
PAF

case had controlled hypertension. No other organic
heart diseases and stroke complications
were founded in all patients. Left atraium was
38.7±3.2 mm and LVEF was 58.6±4.3 on
echocardiography. Repetitive P' on T atrial
prematures and PAFs were confirmed by regular
ECG (Figure 1) and Holter monitoring.

Electrophysiological Study
After written informed consents were obtained,
regular electrophysiological studies were conducted
to exclude atrioventricular reentrant tachycardia
(AVRT) with accessory pathways (AVAP),
atrioventricular nodal reentrant tachycardia
(AVNRT) and other inducible tachyarrhythmias. The
methodology of standard electrophysiological study
was reported elsewhere and briefly described as
follows. A decapolar elctrode catheter was placed in
the distal coronary sinus via left subsclavicle vein.
A tetrapolar electrode catheter (Josephson curve) was
put at His bundle branch and another catheter
(Cournad curve) was settled at the high right atrium
at first and then right ventricular apex. Both
programmable and non-programmable electrical
stimulations were conducted via high right atrium and
right ventricular apex electrode pairs with two times
of diagnostic threshold value and 0.5 ms pulse width.
AVRT and AVNRT were not found according to their
electrophysiological criteria. PAF could be induced
with high rate burst pacing at distal coronary sinus
in two patients.

July/October 2004

J HK Coll Cardiol, Vol 12

LU ET AL.

(A)
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Figure 1. Twelve lead ECG during sinus rate (A) and paroxysmal atrial fibrillation (B).

Pulmonary Vein Identification
and Geometry Creation
Twice transseptal puncture was achieved with
L1 and R1 Swartz sheaths. A large-tip ablation
catheter (Bard Co., 7F) and a non-contact balloon
mapping catheter were introduced into left atrium
(LA). The tip of the balloon mapping catheter was
mounted at the left superior pulmonary vein with a
0.035 inch wire. Pulmonary vein angiographies were
conducted to evaluate their orifices and branches
(Figure 2A). LA geometry was constructed under
either sinus rhythm or PAF using Ensite3000 Navx
system (Figure 2B) and the large-tip ablation catheter
as land mark in LA chamber. On the three-dimension

J HK Coll Cardiol, Vol 12

geometry of LA, two ablation loops and two ablation
lines for electrical isolation were outlined. The two
loops encircled left and right sided pulmonary vein
orifices respectively. The top line connected two
loops on the roof of LA and the bottom line linked
between the lower part of the left loop and the lateral
part of mitral valular ring.

Radiofrequency Catheter Ablation
Along with the loops and lines, radiofrequency
ablation was delivered to form continuous lesion by
the direction of Ensite3000 Navx system. Each lesion
point was ablated in 30 seconds with preset

July/October 2004
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(B)

(A)

Figure 2. (A) Left superior pulmonary vein angiography through a trans atrial septal sheath
positioned at the pulmonary vein ostium. (B) Configuration of a novel three-dimensional electroanatomical mapping system Ensite3000 Navx.

temperature 50°C and energy 30W. The
disappearance or 80% decrease of the amplitude of
target potential and 10 to 20 Ω decrease of ablation
impedance were used as effective index. Altogether
59-126 (63.7±11.2) lesion points were needed to
complete the two loops and two lines (Figure 3). Then
activation mapping in sinus rhythm on threedimensional geometry was repeated to confirm the
electrical disconnection between PVs and LA. Rapid
burst pacing up to 600 beats per minute was delivered
from the distal coronary sinus electrode pair to
provoke PAF. After that, the geometry of right atrium
was constructed by withdrawing the balloon and
ablation catheter. Radiofrequency lesion line between
tricuspid ring and inferior vena cava was achieved
with another 6 lesion points (Figure 4). The procedure
time was 2.8±0.7 hours and fluoroscopy time was
19.6±8.3 minutes. Total 10 mg morphine was injected
intravenously during the period of energy delivery.

Follow Up
The patients were discharged with long-term
oral warfarin and without any antiarrhythmic agent.
61

During the follow up of 5.6±2.3 months, one patient
was free of symptom and PAF attacks were decreased
more than 80% in the other two patients by evaluation
of Holter monitoring.

Discussion
Most focal PAFs could be cured by completely
isolating target pulmonary vein electrically.1-4 PV
isolation could be achieved by spike potential guided
catheter ablation at its orifice or by geometry
mapping guided circular isolation on the LA wall just
near its orifice.5,6 Different procedures have the different
procedure end point and long-term effect.7,8
Spike potential guided ablation or segmental
PV ostial ablation under X-rays suffered with
technical challenges associated with identification of
PV potential, complete electrical isolation, long
distance of PV-LA junction, focus mapping within
target PV, irregular PV orifice, long operation and
X-ray exposure time, and potential PV stenosis.4,6-8
In contrast, left atrial wall ablation near PV orifice
guided by non-contact electro-anatomical mapping,5
which includes two lesion loops around the left and
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Figure 3. Total 59 ablation points were used to complete two loops and two lines.
The two loops encircled left and sided pulmonary veins respectively (A-G). The
top line connected two loops on the roof of LA (D, E, G) and the bottom line
linked between the lower part of left loop and the lateral part of mitral valular
ring (C, D). (A) Lesion on RAO view. (B) Lesion on left lateral view. (C) Lesion
on mitral isthmus. (D) Lesion on PA view. (E) Lesion on right lateral view.
(F) Lesion on AP view. (G) Lesion on cranial view.

(A)

(B)

Figure 4. Posterior isthmus ablation. (A) A radiofrequency ablation line between tricuspid ring and inferior vena cava was
achieved with 6 lesion points.(B) Three dimensional activation mapping showed posterior isthmus conduction block.
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right-sided PVs, one lesion line on the roof of LA
between two loops, and one lesion line from left loop
to the mitral valular ring, can overcome above
disadvantages and achieve complete PV isolation.
The two lesion lines also have the effect of LA atrial
flutter prevention.
From these cases, it is found that Ensite3000
Navx guided LA wall ablation near PV orifice to cure
PAF is safe and feasible and has the advantages of
clear procedure endpoint, shorter X-ray exposure, less
complication and satisfactory long-term effect. Large
number case experience and long-term follow up data
are needed to validate these primary results.
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Prognostic Value of High-Sensitivity C-reactive Protein in Patients
with Chronic Heart Failure
CHUNCAI XUE,1 YING FENG,2 JINSHAN WO,3 YIGANG LI4
From 1Department of Cardiology, The People's Hospital of Binzhou City, Shandong, China; 2Department of Radiation
Oncology, Medical College of Wisconsin, Milwaukee, USA; 3Department of Cardiology, The Medical School Hospital
of Qingdao University, Shandong, China; 4Department of Cardiology, Xinhua Hospital Affilated to Shanghai Second
Medical University, Shanghai, China
XUE ET AL.: Prognostic Value of High-Sensitivity C-reactive Protein in Patients with Chronic Heart Failure.
Objectives: To determine whether High-Sensitivity C-reactive Protein (hsCRP) has Prognostic value in patients
with chronic heart failure. Methods: Serum hsCRP levels were measured with high-sensitivity assay (IMMAGE
Immunochemistry Systems) in 128 patients with CHF and 25 healthy control subjects. Cardiac troponin T (TNT) was
measured by Electrochemiluminescence immunoassay on Elecsys1010 automatic analyzer. Cardiac events were
defined as cardiac death and rehospitalization because of worsening heart failure during a mean follow up period of
378±26 days. Results: Circulating levels of hsCRP and TNT were significantly higher (3.85±4.25 mg/L, 0.21±0.15
mg/L, respectively) in patients with CHF than in 25 healthy people (p<0.01, p<0.01, respectively) and increased
with severity of CHF. During a mean follow up period of 378±26 days, forty-two (32.8%) of the 128 patients had
cardiac events. Levels of hsCRP and TNT were significantly higher (p<0.001, p<0.001, respectively) and left
ventricular ejection fraction (LVEF) was significantly lower (p<0.01) in patients with cardiac events than in patients
without cardiac events. When multivariate Cox proportional hazards analysis was performed, we could find that
hsCRP, TNT, and LVEF were independent significant predictors of cardiac events in patients with CHF. (hsCRP:
hazard ratio[HR], 3.81; 95%CI, 2.14-9.35; P=0.024; TNT: HR, 2.61; 95%CI, 1.96-4.31; P=0.012; LVEF: HR,
3.52; 95%CI, 2.36-10.37; P=0.024). A positive correlation was observed between hsCRP and TNT (r=0.493,
p<0.01). A negative correlation was observed between hsCRP and LVEF (r=-0.354, p<0.01). Conclusion: Serum
hsCRP concentrations were elevated in patients with CHF and increased with severity of CHF. It was an independent
significant predictor of cardiac events in patients with CHF. (J HK Coll Cardiol 2004;12:64-69)
Congestive, C-reactive protein, heart failure, prognoses
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Introduction

Table 1. The characteristics of patients with CHF

The serum concentration of C-reactive protein
(CRP) is mildly elevated in patients with chronic
congestive heart failure (CHF). Standard assay for CRP
lack the sensitivity within the low reference range and
thus cannot be used effectively for routine clinical risk
prediction. Our study was aimed at investigating highsensitivity assay of CRP (hsCRP), a marker of systemic
inflammation, in the context of heart failure, and to
determine if it has prognostic value in patients with
CHF.

Methods
Patients
A total of 128 patients (Chinese) with chronic
heart failure were enrolled in this study. The
diagnosis of chronic heart failure (CHF) was based
on the criteria below produced by the European
Society of Cardiology:1
1. Symptoms of heart failure (at rest or during exercise)
2. Objective evidence of cardiac dysfunction (at rest)
3. Response to treatment directed toward heart failure
(in cases where the diagnosis is in doubt)
The characteristics of patients with CHF were
summarized in Table 1.
All patients had a left ventricular ejection fraction
(LVEF) <40% or had a mean left ventricular endsystolic dimension >55 mm by transthoracic
echocardiography. Ischemic CHF was diagnosed by
coronary angiography (>50% luminal diameter
narrowing in at least 1 major epicardial coronary artery)
or by the history of documented myocardial infarction.

65

No. of patients
Age (y)
Sex M/F
No. of diabetics
No. of smokers
Cause of CHF
Ischemic CHF
Non-Ischemic CHF
NYHA n (%)
Class II
Class III
Class IV
Left ventricular ejection fraction
All patients with CHF
Ischemic CHF
Non-Ischemic CHF
Class II
Class III
Class IV

128
62±15
79/49
19
35
75
53
57 (44.5%)
40 (31.3%)
31 (24.2%)
0.37±0.11
0.36±0.09
0.33±0.08
0.36±0.12
0.27±0.12
0.19±0.13

Non-Ischemic CHF was caused by primary dilated
cardiomyopathy (26 patients), valvular heart disease (15
patients), systemic hypertension (12 patients). We
excluded patients with clinical or laboratory evidence
of systemic infection, myocardial infarction within 8
months, pericarditis, cor pulmonale, inflammatory
illness such as arthritis or connective tissue diseases,
any malignancy tumor.
Control population consisted of 25 healthy
Chinese people (men 15, women 10, mean age 59±16
years old). Blood samples from patients were obtained
on the first day of admission. Control blood samples
from 25 healthy people were obtained at fasting
condition. Blood samples were allowed to clot for 30
minutes at room temperature and were centrifuged for
5 minutes. All blood samples were measured without
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frozen within 3 hours after blood samples were obtained.
All patients were followed up by telephone, or through
regular outpatients visits, or when they were
rehospitalized. Mean follow up period was 378±26 days.
Cardiac events was defined as cardiac death and
rehospitalization because of worsening heart failure.

Measurements of hsCRP and TNT
hsCRP was measured by immunoassay with an
autoanalyzer (IMMAGE Immunochemistry Systems,
Beckman Coulter, California). The intra-assay and
inter-assay coefficients of variation for hsCRP were 5%
and 10%, respectively. TNT was measured by
Electrochemiluminescence immunoassay with
Elecsys1010 automatic analyzer (Roche Company).
Inter-assay and intra-assay coefficient of variation were
<4% and <7% respectively. The level of sensitivity is
<1 pmol. LVEF was obtained by 2-dimensional
echocardiography with HDI 3000 echocardiograph
(ALT Company America).

Statistical Analysis
Data were expressed as mean±SD. Patients were
divided into 3 groups according to their NYHA
functional classification. Analysis of variance test was
used to compare the difference of the levels of hsCRP
and TNT among these 3 groups and the 25 control
subjects. The correlation between the levels of hsCRP
and TNT, hsCRP and LVEF were assessed by using
Linear regression analysis. Cox proportional hazards
analysis was performed to determine the significance
of age, sex, LVEF, presence of ischemic heart disease,
the use of statin drugs, and circulating levels of hsCRP
as independent predictors of CHF. Patients were divided
in 2 groups, patients who had major adverse cardiac
events and those who were event-free. T-test for
measurement data and chi-square test for enumeration

data were performed to compare clinical and
hemodynamic characteristics in these 2 groups.

Results
Circulating levels of hsCRP and TNT were
significantly higher (3.85±4.25 mg/L, 0.21±0.15 mg/L,
respectively) in patients with CHF than in 25 healthy
people (p<0.01, p<0.01, respectively) and increased
with severity of CHF. These data were shown in
Table 2. Patients with CHF were divided in 2 groups
according to the causes of their CHF (ischemic vs nonischemic), serum levels of hsCRP had no significant
difference between the 2 groups (4.13±5.12mg/L vs
4.09±5.24 mg/L, p>0.05).
During a mean follow up period of 378±26 days,
forty-two (32.8%) of the 128 patients had cardiac events.
Patients with CHF were divided into 2 groups, patients
with cardiac events and those who were event free.
There were no significant differences in age, sex, causes
of CHF, or medications between the 2 groups. However
levels of hsCRP and TNT were significantly higher
(p<0.001, p<0.001, respectively) and LVEF was
significantly lower (p<0.01) in patients with cardiac
events than in patients without cardiac events. This data
was shown in Table 3.
When multivariate Cox proportional hazards
analysis was performed, we could find that hsCRP,
TNT, and LVEF were independent significant predictors
of cardiac events in patients with CHF. (hsCRP: hazard
ratio [HR], 3.81; 95%CI, 2.14-9.35; P=0.024; TNT: HR,
2.61; 95%CI, 1.96-4.31; P=0.012; LVEF: HR, 3.52;
95%Cl, 2.36-10.37; P=0.024). A positive correlation
was observed between hsCRP and TNT (r=0.493,
p<0.01). A negative correlation was observed between
hsCRP and LVEF (r=-0.354, p<0.01).

Table 2. The concentrations of hsCRP, TNT in patients with CHF and contral subjects
hsCRP (mg/L)
TNT (mg/L)

Control
1.01±0.54
0.003±0.001

J HK Coll Cardiol, Vol 12

Class II
2.64±3.12
0.143±0.15

Class III
4.51±5.21
0.215±0.17
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Class IV
6.34±7.36
0.45±0.19

P
<0.01
<0.05
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Table 3. Characteristics of patients who had cardiac events and those who were event free
Age (y)
Male (%)
Causes of CHF
Ischemic
Non-ischemic
Medications
Diuretic
Digitalis
β-blockers
ACEI/ARB
Statins
LVEF
hsCRP (mg/L)
TNT (mg/L)

Cardiac events (n=42)
59±8
26 (62%)

Event free (n=86)
62±9
53 (62%)

P
NS
NS

24
18

51
35

NS
NS

39
34
22
32
10
0.22±0.14
6.59±7.69
0.48±0.11

84
70
43
68
21
0.36±0.15
2.46±3.25
0.11±0.02

NS
NS
NS
NS
NS
P<0.01
P<0.001
P<0.001

NS: non significance

Discussion
CHF is the final common pathway of a variety
of cardiac disorder, including ischemic heart disease,
idiopathic dilated cardiomyopathy, and valvular
disease, and is usually progressive. Recent studies
suggest that heart failure may, in part, be an
inflammatory disease.2-4 CRP, an acute phase reactive
protein that increases during the host response to
tissue injury, including that caused by infection,
trauma, malignant disease and chronic inflammatory
conditions,5 is synthesized in the liver, and its serum
concentration is a reliable index of overall
inflammation activity. Several large-scale
prospective epidemiological studies have shown that
plasma levels of hsCRP are a strong independent
predictor of risk of future myocardial infarction,
stroke, peripheral arterial disease, and vascular death
among individuals without known cardiovascular
disease. 6-10 Several studies have shown increased
concentration of CRP in patients with heart failure,11-15
but clinical data about the prognostic value of CRP in
patients with chronic heart failure have been sparse and
inconsistent.11,12,16 Because standard assays for CRP
lack the sensitivity needed to determine levels of
inflammation within low reference range, and thus

67

clinical utility of standard CRP is extremely limited to
its prognostic values in patients with CHF. More
recently, with the recognition that inflammation is one
of the mechanisms of CHF and with the availability of
highly sensitive assay systems, we thought that
circulating concentrations of hsCRP may have
prognostic value in patients with CHF.
Our study demonstrated that serum hsCRP
concentration were elevated in patients with CHF and
increased with severity of CHF. Furthermore, this
study had shown that elevated serum hsCRP
concentrations have independent significant
predictive value. In our study we also found that
hsCRP had a positive correlation with TNT and had
a negative correlation with LVEF. The clinical and
basic studies had shown that CRP has a fundamental
role in atherogenesis. 17 Coronary artery disease was
present in 68% of patients with CHF,18 which cause,
in part, elevated serum hsCRP in patients with CHF.
This study also shown that increased hsCRP levels
in patients with CHF was unrelated to the causes of
heart failure, which suggests that CHF is the final
common pathway of a variety of cardiac disorders,
including ischemic heart disease, idiopathic dilated
cardiomyopathy, and valvular heart disease.
Previous studies observed elevated serum levels
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of TNT in patients with CHF, 19-21 and their presence
was associated with adverse outcome.17 Our results are
consistent with the emerging concept that cardiac
troponin elevations reflect ongoing myocardial cell
injury associated with the progression of CHF. Also,
the present study showed a positive correlation between
TNT and hsCRP, speculating that markers specific for
myocardial cell injury or inflammatory effect may detect
different features of the pathophysiologic process of
heart failure.
The mechanisms underlying the pathogenesis and
progression of CHF remain unclear. Different
mechanisms may be involved, such as activations of
sympathetic nerve and renin-angiotensin-aldosterone
systems. Both experimental and clinical studies have
also shown a role for inflammation in the pathogenesis
of heart failure. There is evidence that chronic activation
of the immune system exists during heart failure. Some
patients present evidence of monocyte-macrophage and
lymphocyte activation.22-25 It appears clear that patients
with either ischemic or non-ischemic heart failure show
activation of proinflammatory cytokines (IL-1, IL-6,
tumor necrosis factor-α). Interleukin-6 is a major
inducer of CRP.26 Cardiac decompensation itself and
injuries to other organs such as the liver, kidney, brain,
or skeletal muscle induced by low cardiac output,
hypoperfusion, hypoxia, and venous congestion may
each be sources of interleukin-6, which may in turn
result in the production of CRP in patients with CHF.27
CRP has many pathophysiologic roles in the
inflammatory process.28 It can amplify the inflammatory
response through complement activation, which may
cause myocardial cell apoptosis, and thus ventricular
damage or dysfunction.29 This may resulted in mildly
elevated levels of serum TNT in patients with CHF. In
our study we found that hsCRP had a negative
correlation with LVEF, this indicated a correlation
between hsCRP and myocardial cell damage.
Whether CRP is simply a marker of chronic
systemic inflammation or directly involved in the
pathogenesis of CHF? Whether it can be used as a target
for treatment of CHF? Further studies will be needed
to answer this question.
In conclusion, serum hsCRP concentrations were
elevated in patients with CHF and increased with
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severity of CHF. It was an independent significant
predictor of cardiac events in patients with CHF.
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Dynamic Characteristics of Heart Rate and Systolic Blood Pressure
at Early Exercise Test after Myocardial Infarction in Predicting
the Life Expectancy
KAMIL LAIMUT BLOZNELIEN , REMIGIJUS ALI NAS, JULIJA BRA D IONYT , INA BLU AIT ,
REGINA GRYBAUSKIEN , LAIMA TALIJ NIEN , GABIJA PUNDZI T
From Kaunas University of Medicine Institute of Cardiology, Kaunas University of Medicine Clinic of Cardiology,
Kaunas, Lithuania
BLOZNELIEN ET AL.: Dynamic Characteristics of Heart Rate and Systolic Blood Pressure at Early Exercise
Test after Myocardial Infarction in Predicting the Life Expectancy. During 11 years period submaximal exercise
testing within 3 weeks of acute myocardial infarction was performed with 894 patients. Exercise induced ST segment
depression appears to have prognostic significance of subsequent development of fatal coronary events at 6, 12, 24
months and 11 years post infarction. At follow-up at 2 years post infarction in the non survivors group there were
only 45.2% exercise induced ST segment depression. This shows, that prognostic importance of ST depression is
insufficient and demands of research of more consistent signs. The cardiovascular response to exercise was interpreted
as transiting process of the self-regulation of cardiovascular system, and the new predictive signs were found on the
basis of heart rate and systolic blood pressure curves during the exercise and after it. The prognostic value of these
signs were established. The combined use both the new predictive signs and the usual data of early exercise test
shows the high predictive possibility of test – the early cardiac death was predicted in 80% of cases. The patients
after myocardial infarction can be divided into relative high and low-risk groups for subsequent cardiac events if all
information available on the exercise test is used. (J HK Coll Cardiol 2004;12:70-74)
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Introduction
Despite the rise and spread of new diagnostic
methods, exercise electrocardiography still remains the
cornerstone of non-invasive evaluation and is almost
uniformly performed after myocardial infarction (MI).1
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This test is usually performed (in case of absence of
contraindications) to all the patients after MI before the
discharge. The prognostic value of the exercise test is
not enough investigated despite of the high percentage
of the persons dying suddenly after MI. The evaluation
of depression of ST-segment in exercise test in
predicting the prognosis after MI is not uniform.1-3
According to the literature and our data, sudden death
during 6 months after MI is closely related to the lifethreatening arrhythmias, detected in early exercise test
after MI. This relation could not be established after
MI later.4,5 It is considered the value of the exerciseinduced QT dispersion (as a sign of ventricular
depolarisation inhomogeneity) in predicting ventricular
arrhythmias and sudden cardiac death.6 The data are
contradictory in assessing which exercise test
parameters are related with survival over 6 months after
MI. 7 Some authors regard to ST-depression as a
borderline parameter and the main attention pay to the
workload, which was obtained during the exercise. This
sign is closely related to the survival over 10 as well as
15 years after MI.8 Heart rate (HR) and blood pressure
(BP) changes represent the cardiovascular response to
the exercise. The aim of our study was to evaluate the
prognostic capability of these signs and to design the
prognostic system capable to pick up patients with high
risk of coronary death during 2 years time after MI,
using the data of early exercise testing.

Patients and Methods
A total of 894 patients (aged 50.68±9.29 years; 827/
92.5% males and 67/7.5% females) admitted to Kaunas
Medical University Hospital have met the eligibility
criteria and were put through submaximal exercise
testing within 3 weeks of the onset of acute MI. Cases
of noncardiac deaths, patients living outside Kaunas or
those subjected to coronary bypass surgery were
excluded from the further analysis. Kaunas Acute
Myocardial Infarction Register was used for survival
(12 months - 11 years) analysis. At the end of 2 years
after MI there were 426 survivors (group I) and 42 cases
of cardiac death (group II). After 11 years there were
98 coronary deaths.
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The submaximal exercise testing (25 W
incremental loading every 3 minutes) was performed
within 3 weeks after acute myocardial infarction. A 12
lead ECG was continuously monitored throughout the
test and 10 minutes after it. A blood pressure was
measured before the exercise test and every minute
during and 10 min. after the test. The occurence of
significant anginal pain, ventricular tachycardia, major
conduction abnormalities, ST-depression >2 mm,
limiting symptoms (such as dyspnoea, dizziness,
fatigue, cramp in legs, etc.), an excessive increase
(above 230 mmHg) or decrease (>30 mmHg) in systolic
blood pressure were regarded as interruption criteria.
Both ST depression in one or more leads, excluding
aVR and V1, and ST elevation in leads without
pathological Q waves were considered. The exerciseinduced angina pectoris and/or the presence of
horizontal or downsloping ST depression of 1 mm
measured 80 ms after J point and of ST elevation of
1 mm measured 40 ms after the J point were regarded as
positive criteria. Positive was defined as low-threshold
if occuring at workload <75 W (450 kgm/min).

Results
Results of exercise testing 3 weeks after MI were
as follows: mean peak workload differed significantly
between the two groups: 44.5±0.9 W (267±5.4 kgm/
min) in group I and 34.2±3.5 W (205.2±21 kgm/min)
in group II (p<0.01). The exercise testing elicited angina
and/or ST depression of >1 mm (ischemic response) in
132 (31%) patients of group I and in 24 (57.1%) patients
of group II (p<0.01). ST depression of >1 mm was
detected in 33 (7.8%) and in 19 (45.2%) cases respectively
(p<0.01). Exercise test positive ST-segment only was
detected in 17 (4 %) patients of group I and in 9
(21.4%) patients of group II (p<0.01). Indicators for
electrical instability (exercise induced serious
ventricular arrhythmias) showed no significant
differences between the groups in 21 (4.9%) patients
of group I and in 4 (9.5%) patients of group II (p>0.3).
The patients of group I had better exercise capacity and
ST depression was registered only in 7.8 % of patients
as compared with 45.2% of patients of group II.
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Our patients were in good functional state at entry
(no patients had a contraindication to exercise);
nonetheless, there were 8.5% of cardiac deaths within
the first two years among the acute MI survivors. Among
those dying within the first two years, only 45.2% had the
exercise-induced ST segment depression. This shows
that the prognostic value of ST depression is not
sufficient and demands research of more consistent
signs.
The cardiovascular response to exercise was
interpreted as a transition process in the self-regulation
of cardiovascular system (system's reaction to the
stress). The survival was predicted by the shape of heart
rate (HR) and systolic blood pressure (BP) curves (their
dynamic characteristics) during exercise testing and
after it. The signs specific to cardiovascular response
to exertion were selected as follows: (1) the extent of
systolic BP changes at the beginning of the exercise
testing; (2) the extent of HR changes at the beginning
of the exercise testing; (3) the character of HR changes
one minute after the exercise discontinuation; (4) the
character of systolic BP changes one minute after the
exercise discontinuation (5) the correlation strength
between the HR and systolic BP curves within the
exercise test; (6) the character of HR curves at rest after
the exercise; (7) the character of systolic BP curves at
rest after the exercise; (8) the character of HR changes
at the last minute of exercise; (9) the character of systolic
BP changes at the last minute of exercise. The prognostic
value of these signs was determined. A combined use
of both, the usual data (indicators for residual
myocardial ischaemia) and the new signs – dynamic
characteristics of HR and BP curves considerably
increased the predictive power of the test. Each sign
included several manifestations. For example, the
character of systolic BP and HR changes at the
beginning of the exercise testing may be manifested by
the different degrees of change intensity, BP and HR
may increase and decrease, with or without delay. All
these specific features are described as characteristic
of sign. All the data obtained in exercise testing in the
early period of MI was divided in two parts. One, named
group C, was used as a learning assembly. In this C
group we chose all cases of death in 0.5 year after MI
and named this group A; all cases of death in the period
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between 0.5 and 2 years after MI and named this group
B. So the remaining group D included the cases with
no death in the period of 2 years after MI. D=C-(A+B).
Then the prognostic value in prediction of the
high risk of coronary death of characteristics of signs
was determined. For this purpose we computed the
frequency rate of each characteristic of all the signs in
group A, A+B, C and D, and denoted frequency rate of
x-characteristic of i-sign in the group A as iϕA(x), in the
group A+B as iϕA+B (x), in the group C as iϕC(x) and in
the group D as iϕ D(x). If the frequency rate of xcharacteristic is the same or nearly the same in group A
as in group C or D, this characteristic has no prognostic
value. In contrast, if the value of frequency rate in group
A is considerably greater in comparison with C or D,
this characteristic has higher prognostic value, higher
informativity. We denote informativity as a relation:
i

σA(x) =

i
i

ϕA(x)

ϕD(x) ;

i

σA+B(x) =

i

ϕA+B(x)
ϕD(x) ;

i

We reject σ(x) if σ(x) <1.5.
We denote the prognostic power of characteristic
of sign by following expressions:
i

i

ξA(x) = 10 ⋅ iσA(x) ⋅ iϕA(x)

ξA+B (x) = 10 ⋅ iσA+B (x) ⋅ iϕA+B (x)

After evaluation of separate characteristics of
sign, the prognostic power of sign is determined as a
set of selected prognostic powers of characteristics of
this sign
n

Pi =

Σ ξ (x )
i

j=1

j

xj , xl ,... xn are denominations of characteristics
of sign.
An example (for sign SAFP - the extent of systolic
BP changes at the beginning of exercise test):
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If

SAFP (x = D1), then 1ξA(D1) = 4.4
SAFP (x = D2), then 1ξA(D2) = 3.5
SAFP (x = D5), then 1ξA(D5) = 1.9
SAFP (x = m), then 1ξA(Dm) = 2.6

72

EXERCISE TEST AFTER MYOCARDIAL INFARCTION

Here D1, D2,... m - are concrete manifestations
(characteristics) of sign.
The same method is used for evaluation of other
signs:
P2, P3,...Pn
The full prognostic power
n

Pi
Πz = Σ
j=1

A

n - the number of used signs, z - identificator of
individual.
In accordance with this method, a programme for
the computer was developed, and with this programme
the values of

Π

A

z

Π

and

A+B

z

for each member of group "C " were estimated.
It was found that with increase of numeral
quantity of prognostic power the risk of coronary death
after MI increases.
After computation of prognostic power of each
member in groups A, A+B, C and D, the arithmetical
mean of prognostic power of each group V d , V d , V d
d
and V was estimated (obtained):
A

A+B

C

D

VA = 28.66; VA+B = 31.05; VC = 23.45; VD = 21.0.
These quantities may by used as criteria to pick
up the patients with high risk of coronary death. The
same method was applied for evaluation of prognostic
values of widely accepted data of early exercise testing.
The combined use of both the widely accepted data of
early exercise testing and the dynamic characteristics
of HR and systolic BP considerably increased the
predictive power of the test. Computation of arithmetical
mean of prognostic power gave following quantities
b

b

b

b

VA = 40.69; VA+B = 39.83; VC = 27.55; VD = 26.82.
After these investigations with the learning
assembly and determination of prognostic power of
signs, an examination on the other part of data of early
exercise testing was performed It demonstrate that early
cardiac deaths were correctly predicted in 80% of cases.
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Discussion
It is known that the double product (BPxHR/100)
attained during the exercise test represents the survival
prognosis and the decrease of BP during the exercise
correlates with unfavourable outcomes.5 According to
our data, exercise induced hypotension was registered
more frequently in the group of survivors. 9 The
hypotension was established in 8.6% of the survivors
and in 7.16% among those dying within the first 6
months after MI. In the group of 1-year survivors after
MI, exercise hypotension was established in 9% of
patients and in non-survivors – in 3.1% of cases. Two
years after MI the results were 9.2% and 2.4%
respectively. Hypotension in early exercise test was
detected in 10% of patients in the group of 10 years
survivors and in 5.1% of patients dying during this
period after MI. Our patients undergoing early exercise
test after MI were in relative good physical condition,
without any contraindications for the test. In this case
we can explain the relative rare hypotension cases in
our early exercise tests after MI and no established
correlation to the unfavourable outcomes. According
to our data, dynamic of BP and HR during the exercise
and after it were related to survival after MI.
It is important to pay attention to such easy
detectable marker of sudden cardiac death – absence of
T-wave pseudonormalisation during the early exercise
test after MI. This sign is not enough investigated. There
is an opinion,10 that this could be related to the absence
of the metabolic myocardial activity. Necrotic
myocardium has no metabolic and electrical activity,
so in these cases negative T-waves can not undergo the
changes (absence of pseudonormalisation). Our data
revealed, that in the group of 11 patients dying suddenly
during the first 6 months after MI, all of them
had negative T-waves in the zone of infarction. Ten
(90.9%) of them had no T-pseudonormalisation pattern
during the exercise test. Negative T-waves at the third
week after MI were detected in 58 (66%) of 87 patients
dying during 10 years after MI. The early exercise test
did not induce T-pseudonormalisation in 21 (36.2%) of
these patients (significantly lower (p<0.01) as compared
to the death cases during the first 6 months after MI).11
Thus, our data showed, that the absence of T-wave
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pseudonormalisation during the early exercise test after
MI may predict early sudden death after MI.

Conclusion
In conclusion, patients after MI can be divided
into relative high and low-risk groups for subsequent
cardiac events if all information available on the
exercise test is used. The use of the dynamic
characteristic of heart rate and systolic blood pressure
considerably increase the predictive power of the test;
the early cardiac deaths being correctly predicted in 80%
of cases.
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The Role of Adrenomedullin in the Cardiovascular System
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WONG ET AL.: The Role of Adrenomedullin in the Cardiovascular System. Adrenomedullin (AM) is a 52 amino
acid peptide that was first isolated from human pheochromocytoma. Subsequently, AM and its receptors are found to
be distributed widely in the body, including the cardiovascular system. It belongs to a family of peptides that include
calcitonin gene-related peptide. In blood vessels, AM causes vasodilation and regulates proliferation. It interacts
closely with nitric oxide and has a role in the pathophysiology of hypertension, ischaemic heart disease, cardiac and
renal failure. A non-peptide analogue of AM or gene therapy may be of potential therapeutic use. The role of AM in
septicaemic shock also merits further investigation. (J HK Coll Cardiol 2004;12:75-81)
Adrenomedullin, cardiovascular system, nitric oxide, peptide, vasodilation

5 2

Introduction
Adrenomedullin (AM) was first discovered in
1993 by Kitmura and co-workers as a new peptide from
human pheochromocytoma with its ability to raise cyclic
adenosine 3'-5'-monophosphate (cAMP) levels in
platelets.1 Subsequently, AM had aroused much interest
because of its potent and long lasting depressor effect
when injected intravenously into the rat.2 Human AM
consists of 52 amino acids and has a ring structure
formed by one intramolecular disulfide bond and an
amidated carboxyl terminal, structures that are essential
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for its bioactivity. It belongs to a family of peptides
that include calcitonin gene-related peptide (CGRP) and
amylin.3 These peptides bind to either the calcitonin or
the calcitonin receptor-like (CL) receptor.
The human AM gene is located at the single locus
of chromosome 11 and consists of 4 exons and 3 introns.4
In the 5'-upstream sequence of the AM gene, several
binding sites for activator protein-1 and activator
protein-2, cAMP-regulated enhancer and a shear stress
responsive element "GAGACC" are present, which play
roles in the transcriptional regulation of AM gene.3 The
circulating form of AM is formed from successive
enzymatic cleavage of a 185-amino-acid
preproadrenomedullin (preproAM) sequence (Figure 1).
Cleavage of a 20-amino acid sequence in the N-terminal
region of proadrenomedullin yields the
proadrenomedullin N-terminal 20-peptide (PAMP),4
which is also a potent vasodilator. Recently, two other
peptides in the family have been identified, namely
long- and short-form intermedin which consist of a 47-
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Figure 1. Schematic presentation of post-translational processing of the human preproadrenomedullin gene product.

amino acid and a 40-amino acid peptide respectively.5
The long form intermedin is also known as AM2. They
also have vasodilatory and hypotensive actions.

Tissue Distribution and Synthesis
AM was originally identified in pheochromocytoma, however, in the process of identifying
AM-secreting cells, it has been shown to be widely
distributed in many tissues and fluids. Immunoreactive
AM is found in the human cardiovascular, renal,
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respiratory, gastrointestinal, reproductive, neurological,
endocrine and immune systems.6 It circulates in plasma
in the low fmol/ml range, and is also present in urine,
cerebrospinal and amniotic fluid. The plasma half-life
of AM in man is 22 minutes and the volume of
distribution is 880 ml/kg.7
Secretion of AM is influenced by physical and
hormonal factors such as shear stress, ventricular wall
stress, hypoxia, cytokines and endocrine and paracrine
hormones. Inflammatory cytokines including tumour
necrosis factor (TNF)-α, TNF-β, interleukin (IL)-1α,
IL-1β, and lipopolysacccharide (LPS) strongly stimulate
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the synthesis and secretion of AM in endothelial cells
and vascular smooth muscle cells (VSMCs).8 Activation
of NF-IL6 mediates the induction of AM expression by
cytokines. 8 In rat, LPS increases AM expression in
various tissues including lung, heart, liver, and kidney.9 In
VSMCs, AM production is also stimulated by
glucocorticoids, thyroxine, angiotensin II, bradykinin
and adrenaline.10

Receptors and Signal Transduction
Specific binding sites for AM are present in rat
heart, lung, spleen, liver, diaphragm, spinal cord and

different parts of the brain, with the greatest density of
binding sites in the heart and lung.11 Initially, AM was
thought to bind to a CGRP receptor, as these related
peptides have overlapping binding sites and vascular
effects. It is now known that a functional AM or CGRP
receptor consists of at least three proteins: the CL
receptor, receptor-activity-modifying proteins (RAMPs)
and a receptor component protein (RCP). 12 Three
subtypes of RAMPs, namely RAMP1, RAMP2, and
RAMP3, have been identified. CL receptor can function
either as a CGRP receptor or an AM receptor depending
on the co-expression of different subtypes of RAMPs
(Figure 2). Co-expression of CL receptor with RAMP1
forms a CGRP receptor while co-expression of CL

Figure 2. CGRP and AM receptors.
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receptor with RAMP2 or RAMP3 results in binding of
AM. These RAMPs may control the transport and
glycosylation of the CL receptor to define the specificity
of receptor. RAMP1 presents CL receptor as a mature
glycoprotein at the cell surface to form a CGRP receptor,
whereas the RAMP2 or RAMP3-transported receptors
are core glycosylated AM receptors.12
The vasodilatory and hypotensive responses
elicited by AM are mediated via at least two
mechanisms: a direct action on VSMCs to activate the
adenylyl cyclase-PKA pathway resulting in increase of
intracellular cAMP, and an action on endothelial cells
to stimulate nitric oxide (NO) release.13 Furthermore,
potassium ion-ATP channel may also be involved in
AM-induced vasodilation in isolated perfused rat kidney
in which the endothelium-derived hyperpolarizing
factor (EDHF) opens the potassium ion channels.14

Cardiovascular Effects
AM plays a major role in the maintenance of
cardiovascular and renal homeostasis.14,15 In addition, it
modulates the hypertrophy of cardiomyocytes and the
growth of fibroblasts, and also have antimicrobial
effects.4 In transgenic mice with one AM allele deleted,
there was increase in blood pressure and decrease in
NO expression,15 suggesting that AM is involved not
only in blood pressure regulation but also in endothelial
function. Infusion of AM into human brachial artery
significantly increases forearm blood flow via a NOdependent pathway that can be blocked by L-NMMA.16
Infusion of AM in man also lowers pulse wave velocity.17
In sheep, intracoronary AM causes vasodilation, also
through the release of NO.18 In Dahl salt-sensitive rats,
AM restores NO-dependent vasodilatation, through
upregulation of NO production and reduction in
superoxide formation.19
Intravenous infusion of AM lowers blood
pressure, and increases heart rate and cardiac output.20
A direct cardiostimulatory effect can also be
demonstrated in the isolated perfused rat heart. 21
However, AM is also negatively inotropic under other
circumstances, such as in isolated rabbit cardiac
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ventricular myocytes, rat papillary muscle and human
left ventricular myocytes. 22 This negative inotropic
effect may be mediated by NO.
Intravenous infusion of AM increases renal blood
flow, glomerular filtration, urine flow and fractional
urinary sodium excretion, and decreases distal tubular
sodium reabsorption independent of blood pressure.23
The natriuresis and diuresis may be mediated via renal
prostaglandin24 and NO.25
As well as regulating vascular tone, AM may also
regulate vascular proliferation and remodelling. It dosedependently inhibits thymidine incorporation and
proliferation induced by platelet-derived growth factor
in VSMCs.26 AM may also be an angiogenic factor.
Vascular density and endothelial cell proliferation are
stimulated by AM. Many tumours express AM; an
antibody against AM or an AM antagonist suppresses
tumour growth in animal models.27 Whether AM can
be used to increase angiogenesis in ischaemia remains
to be explored.

Neuroendocrine Effects
High levels of AM are found in the adrenal
medulla and zona glomerulosa. Intravenous AM
infusion lowers circulating cortisol and adrenocorticotrophic hormone (ACTH) levels in sheep.28 There
appears to be a complex interaction between AM and
the renin-angiotensin system; AM stimulates the release
of renin,29 but inhibits aldosterone secretion.30
AM immunoreactivity is widely distributed in the
central nervous system (CNS). 31 In the supraoptic
nucleus (SON) and in the magnocellular parts of the
paraventricular nucleus (PVN), AM is expressed. As a
neuropeptide, AM may regulate body fluid homeostasis
by inhibiting water drinking and salt appetite. Blockade
of the action of endogenous AM by passive immunoneutralization results in exaggerated sodium appetite.32
By restraining salt and water intake, AM's central actions
complement its renal actions. AM expression is
increased in the ischemic cerebral cortex in the rat after
middle cerebral artery occlusion,33 where it may increase
cerebral blood flow and promote collateral perfusion.
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Plasma AM Levels in Diseases
Plasma AM levels are increased in a variety of
diseases: congestive heart failure, 34 myocardial
infarction,35 renal diseases,36 hypertension,37 diabetes
mellitus, 38 the acute phase of stroke 39 and septic
shock. 40 Plasma AM levels are elevated in patients
with essential hypertension in proportion to the
severity of hypertension, 36 especially in those with
left ventricular hypertrophy. However, neither acute
nor chronic salt loading, nor anti-hypertensive
therapy changes the circulating level of AM in
patients with essential hypertension. Plasma levels
of AM are increased in patients with congestive heart
failure, whether systolic 34 or diastolic. 41 The failing
human heart secretes increased amounts of AM.
Plasma AM concentration correlates with pulmonary
capillary wedge pressure and inversely with ejection
fraction. It decreases after treatment of the heart
failure. Plasma AM concentration is elevated in
relation to the degree of renal failure.36
Injection of LPS in the rat produces a marked
increase in plasma AM, suggesting AM may be
involved in sepsis. 42 Circulating AM level is also
i n c r e a s e d i n s e p s i s i n m a n . 40 I n t h e e a r l y ,
hyperdynamic phase of septicaemia, there is
upregulation of AM, followed by a reduction in
vascular responsiveness to AM in the late,
hypodynamic response.43 Administration of AM and
its binding protein (AMBP-1) maintains
cardiovascular stability and reduces sepsis-induced
mortality.44 Transgenic mice overexpressing AM are
resistant to septicaemic shock.45 Therefore, AM may
be responsible for many of the changes in the
circulatory system in septic shock.

hypertension and heart failure. In AM-knockout mice,
there is accelerated cardiac hypertrophy and renal
damage induced by angiotensin II,48 suggesting that
endogenous AM protects against cardiac and renal
damages. In the rat model of myocardial infarction
induced by coronary artery ligation, a one-off early
intravenous administration of AM prevents
subsequent left ventricular remodelling.49 As AM is
a peptide, it cannot be given orally. In patients with
pulmonary hypertension, AM administered by
inhalation reduced pulmonary vascular resistance. 50
A non-peptide analogue is eagerly awaited for
clinical studies. Neutral endopeptidase inhibitors
increase the level of AM as well as other vasoactive
peptides, but their use is limited by the increased
likelihood of angiooedema. Expression of AM
is known to be increased after angioplasty and
stenting;51 AM gene delivery successfully inhibited
neointimal formation after balloon angioplasty in a
rat model.52 Gene therapy targeting the AM system
is a novel and promising modality of treatment for
the future.

Conclusions
In summary, AM and its receptor are
distributed widely in the body, including the
cardiovascular system. In blood vessels, AM causes
vasodilation and regulates proliferation. It interacts
closely with NO and has a role in the pathophysiology
of hypertension, ischaemic heart disease, cardiac and
renal failure. A non-peptide analogue of AM or gene
therapy may be of potential use in these diseases.
The role of AM in septicaemic shock, a condition
characterised by high mortality, also merits further
investigation.

AM as Therapeutic Agent
Infusion of AM lowers blood pressure in
hypertension 46 and lowers ventricular end-diastolic
pressure and increases cardiac output in heart failure.47
Therapy based on increased stimulation of AM
receptors may have potential application in
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